Physician profile
Leonard Slazinski
NPI 1942368915
$280.72
in general payments reported to CMS, 2019-2025
10 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $73.86 · 2024: $92.58 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $280.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stability Biologics, LLC | $48.79 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $35.54 | 2023-2025 | Libtayo, Dupixent |
| Abbvie INC. | $34.03 | 2023 | Skyrizi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.30 | 2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $27.78 | 2024 | |
| Convatec INC. | $26.98 | 2025 | |
| Sun Pharmaceutical Industries INC. | $25.37 | 2023 | Ilumya |
| Kerecis Limited | $17.43 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Mimedx Group, INC. | $16.89 | 2024 | |
| Tempus Ai, INC | $16.61 | 2024 | Merlin Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Slazinski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.